About Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: HRTX
- Previous Close: $13.75
- 50 Day Moving Average: $13.39
- 200 Day Moving Average: $16.06
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.88
- P/E Growth: 0.18
- Market Cap: $N/A
- Beta: 1.58
- Return on Equity: -218.39%
- Return on Assets: -144.10%
Companies Related to Heron Therapeutics:
- Debt-to-Equity Ratio: 2.80%
- Current Ratio: 3.04%
- Quick Ratio: 2.98%
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2017?
9 equities research analysts have issued 12 month target prices for Heron Therapeutics' stock. Their predictions range from $21.00 to $51.00. On average, they expect Heron Therapeutics' stock price to reach $37.75 in the next twelve months.
When will Heron Therapeutics announce their earnings?
Heron Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
What are analysts saying about Heron Therapeutics stock?
Here are some recent quotes from research analysts about Heron Therapeutics stock:
According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/10/2017)
Cowen and Company analysts commented, "Yesterday Heron released positive Ph 2 abdominoplasty data for HTX-011." (1/6/2017)
Who owns Heron Therapeutics stock?
Heron Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (0.00%), FMR LLC (0.00%), Janus Capital Management LLC (0.00%), Broadfin Capital LLC (0.00%), Highland Capital Management LP (0.00%) and State Street Corp (0.00%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen.
Who sold Heron Therapeutics stock? Who is selling Heron Therapeutics stock?
Heron Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG and Franklin Resources Inc..
Who bought Heron Therapeutics stock? Who is buying Heron Therapeutics stock?
Heron Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Broadfin Capital LLC, Rubric Capital Management LP, Janus Capital Management LLC, Alyeska Investment Group L.P., State Street Corp, Eventide Asset Management LLC and Alden Global Capital LLC.
How do I buy Heron Therapeutics stock?
Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Heron Therapeutics stock cost?
One share of Heron Therapeutics stock can currently be purchased for approximately $13.90.